Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05047302
Other study ID # CLN009
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date November 1, 2026

Study information

Verified date October 2023
Source Intervene, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, non-randomized, multicenter pre-market feasibility study to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 1, 2026
Est. primary completion date November 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. 18 years of age or older; - 2. Symptomatic CVI subjects, Clinical Etiological Anatomical Pathophysiological (CEAP) classification 4 to 6; - 3. Failed at least 6 months of conservative therapy at some point during the course of their CVI management (symptoms not adequately resolved or patient non-compliant/unable to tolerate); - 4. Willing and able to sign the approved informed consent form (ICF); - 5. Willing to comply with follow-up evaluations and protocols; - 6. Deep system venous reflux characterized by >1 second reflux time in two contiguous vein segments (vein segments defined as: proximal femoral, distal femoral, and popliteal), as assessed by DUS with patient in the standing position; - 7. Presence of at least two potential target sites within the target vessel, which is defined as a segment within the femoral or popliteal vein that is: - not less than 7mm in luminal diameter, and - not more than 11mm in luminal diameter, and - at least 3cm long (two target sites in a row must be spaced at least 1cm apart), and - absent severe obstructive features such as thrombus, synechiae, natural valves, major tributaries (valves can be formed opposite tributaries) or severe heterogeneous fibrotic changes of the vessel wall which, in the Investigator's opinion, would preclude formation of a valve, as preliminary assessed by DUS, and then by IVUS, while the vein is under physiologically appropriate hemodynamic pressure, with IVUS being the definitive modality. - 8. In the Investigator's opinion, the subject is a good candidate for treatment with the BlueLeaf System based on their symptoms, quality of life, anatomy, and the likelihood of benefit from continued conservative therapy. Exclusion Criteria: - 1. Untreated significant superficial venous incompetence within 30 days of screening which, in the opinion of the Investigator, may be the primary source of existing symptoms; - 2. A competent vein valve in any vein segment through which the device is likely to be inserted, as assessed by DUS (<1 second reflux time) or with contrast venography (Investigator's opinion);Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent; - 3. Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent - 4. Significant peripheral arterial disease with an ankle-brachial index of <0.70 or with incompressible vessels; - 5. Contraindications to all protocol specified anticoagulation options; - 6. Known and uncontrolled hypercoagulopathy (i.e. hypercoagulopathy that cannot be adequately managed/controlled with medication); - 7. Acute deep venous thrombosis (DVT) within 6 months of consent; - 8. Comorbidity risks or other concerns (e.g. recent cancer) which, in the opinion of the Investigator, limit longevity or likelihood of complying with the protocol and its prescribed follow up or would preclude the patient from open surgery in the event of a complication requiring surgical intervention (e.g. severe vein laceration); - 9. General contraindications to local, regional or general anesthesia required for the index procedure; - 10. NYHA Class III or IV heart failure; - 11. Active systemic infection; - 12. Women on long-term oral contraceptives; - 13. Subject is enrolled in another clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results; - 14. Invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results; - 15. History of stroke within the last 6 months; - 16. Flow-limiting venous outflow obstruction central to the intended target sites, defined by a common femoral vein duplex exam found to have a continuous waveform without respiratory variation or a 50% or greater reduction in luminal cross-sectional area on IVUS; - 17. Inadequate flow into or through the target vessel (Investigator's opinion); - 18. Anatomy that does not support proper device access of the treatment vein through the ipsilateral common femoral or femoral vein; - 19. Luminal diameter <7 mm between the vein access site and the intended treatment site, as assessed by IVUS, while the vein is under physiologically appropriate hemodynamic pressure; - 20. A competent vein valve in any vein segment through which the device is likely to be inserted (common femoral or femoral vein) - 21. Chronic renal insufficiency with creatinine level of =2mg/dL; - 22. Hemoglobin level <9.0 mg/dL; - 23. Platelet count <50,000 or >1,000,000 per mm3; - 24. Total white blood cell count <3,000/mm3; - 25. Pregnant or lactating female; positive pregnancy test, women of childbearing potential must be tested; - 26. Non-ambulatory patients; - 27. Patients with a history of right heart failure occurring as a consequence of, for example, biventricular failure, intrinsic pulmonary disease, chronic thromboembolic pulmonary hypertension, and other etiologies that result in elevated right-sided pressures.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BlueLeaf Procedure
The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Intervene, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Venous Clinical Severity Score (VCSS) A decrease in score from baseline 1 year
See also
  Status Clinical Trial Phase
Terminated NCT02462096 - A Feasibility Study of the ReLeaf Catheter System N/A
Enrolling by invitation NCT05504070 - Venclose digiRF System Post Market Study N/A
Completed NCT05507346 - A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema N/A
Recruiting NCT05622500 - Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease N/A
Completed NCT03283800 - Copper Impact on Venous Insufficiency and Lipodermatosclerosis N/A
Completed NCT01501188 - Efficacy Study of Kinesio Taping to Treat Muscular and Joint Problems in Chronic Venous Insufficiency Phase 1
Completed NCT02236338 - Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein Phase 4
Terminated NCT02248740 - Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein Phase 4
Recruiting NCT05982405 - Long-term Effects of Inspiratory Muscle Training in Chronic Venous Insufficiency N/A
Completed NCT05383469 - Efficacy of Active Versus Passive Methods in Chronic Venous Insufficiency N/A
Completed NCT06238791 - Plantar Pressure Analysis and Foot Biomechanics in Lipedema and Chronic Venous Disease
Withdrawn NCT02559427 - SPA Therapy in the Treatment of Sleep Apnea Syndrome N/A
Completed NCT02346058 - Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins Phase 4
Active, not recruiting NCT05926830 - Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study N/A
Active, not recruiting NCT04339075 - Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingApore
Active, not recruiting NCT04580160 - Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System N/A
Not yet recruiting NCT02927483 - Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency Phase 3
Completed NCT02015221 - Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort N/A
Completed NCT02050061 - Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life N/A
Completed NCT01432795 - Practicability of Gliding Aids for Medical Compression Stockings Phase 4